A Newer Approach in the Treatment of Seborrheic Dermatitis With QR678 and QR678 Neo: A Prospective Pilot Study

August 2023 in “ Journal of Cosmetic Dermatology ”

Rinky Kapoor, Debraj Shome, Komal Doshi, Ghanshyam Patel, Harshal Tandel, Vaibhav Kumar

QR678 QR678 Neo seborrheic dermatitis hair regrowth growth factors vitamins minerals scalp flaking Seborrheic Dermatitis Scalp Severity Index inflammation

Studysummary This study found that intradermal QR678 Neo® therapy improved scalp condition in men and women with seborrheic dermatitis unresponsive to standard treatments, reducing flaking and inflammation after eight sessions, with high patient satisfaction reported.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

13 / 13 results

research Evaluation of Efficacy of Derma Roller Sizes vs Topical Application for Administration of QR678 Neo Hair Regrowth Formulation in the Treatment of Androgenetic Alopecia

September 2022 in “Journal of Cosmetic Dermatology”

This article discusses the efficacy of different derma roller sizes compared to topical applications for administering QR678 Neo® in treating androgenetic alopecia, but provides no new clinical results.

Evaluation of the Safety and Effectiveness of Intradermal Administration of QR678 Neo Hair Growth Factor Formulation: A Phase-IV, Open-Label, Single-Arm Multi-Ethnicity Clinical Trial

research Evaluation of the Safety and Effectiveness of Intradermal Administration of QR678 Neo Hair Growth Factor Formulation: A Phase-IV, Open-Label, Single-Arm Multi-Ethnicity Clinical Trial

2 citations , January 2022 in “Journal of Cosmetic Dermatology”

This study found that intradermal administration of QR678 Neo® significantly reduced hair fall and improved hair growth in patients with androgenetic alopecia and female pattern hair loss, with no side effects reported during long-term follow-up.

Efficacy of QR678 Neo Hair Growth Factor Formulation for the Treatment of Hair Loss in COVID-19-Induced Persistent Telogen Effluvium: A Prospective, Clinical, Single-Blind Study

research Efficacy of QR678 Neo Hair Growth Factor Formulation for the Treatment of Hair Loss in COVID-19-Induced Persistent Telogen Effluvium: A Prospective, Clinical, Single-Blind Study

5 citations , December 2021 in “Journal of Cosmetic Dermatology”

In this study of 20 female patients with Covid-19-induced persistent Telogen Effluvium, intra-dermal QR678 Neo® treatments led to significant reductions in hair fall and increases in hair growth and density, sustained even post-therapy.

Effectiveness of QR678 and QR678 Neo with Intralesional Corticosteroid vs. Intralesional Corticosteroid Alone in the Treatment of Alopecia Areata – A Randomized, Comparative, Prospective Study

research Effectiveness of QR678 and QR678 Neo with Intralesional Corticosteroid vs. Intralesional Corticosteroid Alone in the Treatment of Alopecia Areata – A Randomized, Comparative, Prospective Study

4 citations , November 2021 in “Journal of Cosmetic Dermatology”

The researchers reported that QR678 Neo® combined with intralesional steroids significantly improved hair regrowth and patient satisfaction in treating alopecia areata compared to steroids alone.

Comparison of QR 678 and QR 678 Neo as Monotherapy and Combination Therapy with 5% Minoxidil Solution and Oral Finasteride in the Treatment of Male Androgenetic Alopecia—Which Is Better?

research Comparison of QR 678 and QR 678 Neo as Monotherapy and Combination Therapy with 5% Minoxidil Solution and Oral Finasteride in the Treatment of Male Androgenetic Alopecia—Which Is Better?

3 citations , April 2021 in “Journal of Cosmetic Dermatology”

Combination therapy with QR 678 Neo and 5% Minoxidil is most effective for male hair loss.

Evaluation of Efficacy of Intradermal Injection Therapy vs Derma Roller Application for Administration of QR678 Neo Hair Regrowth Formulation for the Treatment of Androgenetic Alopecia—A Prospective Study

research Evaluation of Efficacy of Intradermal Injection Therapy vs Derma Roller Application for Administration of QR678 Neo Hair Regrowth Formulation for the Treatment of Androgenetic Alopecia—A Prospective Study

4 citations , April 2021 in “Journal of Cosmetic Dermatology”

This study found that both intradermal injection and derma roller techniques for QR678Neo® hair regrowth therapy improved androgenetic alopecia symptoms, with intradermal injections showing non-significantly better video-microscopic outcomes but more pain and erythema associated with derma rollers.

Evaluation of Efficacy of QR 678 and QR678 Neo Hair Growth Factor Formulation for the Treatment of Female Pattern Alopecia in Patients with PCOS—A Prospective Study

research Evaluation of Efficacy of QR 678 and QR678 Neo Hair Growth Factor Formulation for the Treatment of Female Pattern Alopecia in Patients with PCOS—A Prospective Study

4 citations , August 2020 in “Journal of Cosmetic Dermatology”

In this study, QR678® and QR678 Neo® injections significantly improved hair density and thickness in women with PCOS-related alopecia over eight sessions, with effects lasting over a year.

research QR678 and QR678 Neo Hair Growth Formulations: A Cellular Toxicity and Animal Efficacy Study

7 citations , August 2020 in “Plastic and reconstructive surgery. Global open”

In this study, QR 678 and QR 678 Neo formulations containing growth factors and peptides were found to be safe in vitro and promoted hair growth in vivo in an animal model, suggesting their potential as treatments for alopecia, including secondary alopecia post-chemotherapy.

research QR 678 and QR678 Neo vs PRP—A Randomized, Comparative, Prospective Study

14 citations , April 2020 in “Journal of Cosmetic Dermatology”

In this study, intradermal injections of QR678 were found to significantly reduce hair fall in men with androgenetic alopecia over 6 months, with superior improvements in hair density and thickness compared to PRP.

Intradermal Injections of a Hair Growth Factor Formulation for Enhancement of Human Hair Regrowth: Safety and Efficacy Evaluation in a First-in-Man Pilot Clinical Study

research Intradermal Injections of a Hair Growth Factor Formulation for Enhancement of Human Hair Regrowth: Safety and Efficacy Evaluation in a First-in-Man Pilot Clinical Study

17 citations , February 2018 in “Journal of Cosmetic and Laser Therapy”

In this study, researchers administered eight sessions of intradermal injections containing growth factors into the scalp of 1000 patients, reporting a significant reduction in hair fall in 83% of participants and increased total hair count and shaft diameter, with promising tolerance and safety.

research Is Seborrhoeic Dermatitis Associated with Diffuse, Low-Grade Folliculitis and Progressive Cicatricial Alopecia?

15 citations , March 2015 in “Australasian Journal of Dermatology”

This study suggests that seborrhoeic folliculitis may represent a unique form of cicatricial alopecia, linking chronic scalp dermatitis-folliculitis with low-grade inflammatory fibrosing alopecia.

research A Comprehensive Pathophysiology of Dandruff and Seborrheic Dermatitis: Towards a More Precise Definition of Scalp Health

89 citations , January 2013 in “Acta dermato-venereologica”

This review examines dandruff and seborrheic dermatitis, highlighting the role of Malassezia yeasts in inflammation and hyper-proliferation, and reports no new clinical findings.

research Quality of Life in Patients Suffering from Seborrheic Dermatitis: Influence of Age, Gender, and Education Level

59 citations , September 2008 in “Mycoses”

This study found that seborrheic dermatitis significantly worsens patients' quality of life, with stronger effects observed among women, younger individuals, and those with higher education levels.